¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÇ÷°ü¿Ü°úÇÐȸ Á¦73Â÷ Ãá°èÇмú´ëȸ : 2021-04-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÇ÷°ü¿Ü°úÇÐȸ Á¦73Â÷ Ãá°èÇмú´ëȸ : 2021-04-16
±³À°ÀÏÀÚ : 2021-04-16
±³À°Àå¼Ò : BEXCO  
±³À°ÁÖÁ¦ : ´ëÇÑÇ÷°ü¿Ü°úÇÐȸ Á¦73Â÷ Ãá°èÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷°ü¿Ü°úÇÐȸ
´ã´çÀÚ : ±èÇü±â
¿¬¶ôó : 02-1111-1111  
À̸ÞÀÏ : ksvs@chol.com      
±³À°Á¾·ù : ¿Ü°ú, ¿µ»óÀÇÇаúÀÇ»çÇÐ, ÇغÎÇÐ, ÀÇÇб³À°,      
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 3Á¡  
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 3 ½Ã°£ 5ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í • Á¤È¸¿ø Àü¹®ÀÇ:50,000¿ø, ºñȸ¿ø Àü¹®ÀÇ:80,000¿ø, ÁØȸ¿ø, Àü°øÀÇ, °£È£»ç, ±â»ç, ±âŸ:¹«·á • Äڷγª¹ÙÀÌ·¯½º-19 È®»ê ¹æÁö ¹× Á¤È®ÇÑ Âü¼®ÀÚ Àοø ÆľÇÀ» À§ÇÏ¿© À̹ø Ãá°èÇмú´ëȸ´Â ÇöÀåµî·ÏÀ» ¹ÞÁö ¾Ê±â·Î ÃÖÁ¾ °áÁ¤µÇ¾ú½À´Ï´Ù. • ÇöÀå Âü¼®Àº ÁöÁ¤µÈ ¿¬ÀÚ, ÁÂÀå, ÆгÎ, ÃÊ·Ï Ã¤ÅÃÀÚ¸¸ °¡´ÉÇϸç, ÀÌ ¿Ü¿¡´Â ÇöÀå Âü¼®ÀÌ Àý´ë ºÒ°¡ÇÑ Á¡ ¾çÇØ ¹Ù¶ø´Ï´Ù. • °í¹®, ÀÚ¹®, 65¼¼ ÀÌ»ó Á¤È¸¿ø, ÇлýÀº ¹«·á µî·Ï (ÇлýÀº ´çÀÏ ÇлýÁõ È®ÀÎ) • ÇÐȸ ¿¬È¸ºñ¸¦ ³³ºÎÇÑ ´ëÇÑÇ÷°ü¿Ü°úÇÐȸ Á¤È¸¿ø¿¡ ÇÑÇÏ¿© ȸ¿ø µî·Ïºñ°¡ Àû¿ëµË´Ï´Ù. • ¸ðµç Âü¼®ÀÚ Ã¼¿Â ÃøÁ¤ ¿¹Á¤ / ¸¶½ºÅ© ¹ÌÂø¿ëÀÚ ÃâÀÔ ºÒ°¡      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ13:00~14:00 Registration  () 
±âŸ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ14:00~14:05 Opening Address  Çã½Â(´ëÇÑÇ÷°ü¿Ü°úÇÐȸ ÀÌ»çÀå) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ14:05~14:20 (Recorded live case 1) Aortic surgery via retroperitoneal approach: how I do it  ¹Ú¾çÁø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ14:20~14:30 Techniques to avoid visceral/renal ischemia during suprarenal abdominal aortic aneurysm repair  ÇÑ¿µÁø(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ14:30~14:45 (Recorded live case 2) Distal tibial/peroneal bypass: technical tips  ±èÇü±â(°æºÏÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ14:45~14:55 Anastomotic techniques to improve patency in small caliber diseased vessels  È²Á¤±â(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ14:55~15:10 (Recorded live case 3) Carotid endarterectomy: shunt  ¾ç½Å¼®(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ15:10~15:20 Updates on recent trials for carotid artery stenosis treatment  ±èÇâ°æ(¿ï»êÀÇ´ë) 
Åä·Ð 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ15:20~15:30 Discussion  ¹Î½Â±â ¾È¹®»ó ȲȫÇÊ ÀÌÈ£±Õ ¾È»óÇö ³ë¿µ³²(¼­¿ïÀÇ´ë Ãæ³²ÀÇ´ë ÀüºÏÀÇ´ë Àü³²ÀÇ´ë ¼­¿ïÀÇ´ë °è¸íÀÇ´ë) 
È޽Ġ04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ15:30~15:50 Coffee break  () 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ15:50~16:05 (Recorded live case 4) EVAR with endoAnchors: when and how?  ÀÌ»ó¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ16:05~16:20 (Recorded live case 5) EVAR with IBD: indications and limitations  ±è»óµ¿(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ16:20~16:30 EVAR for challenging anatomies: how to improve my technique  À±¿ì¼º(°æºÏÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ16:30~16:45 (Recorded live case 6) Endovascular treatment of multilevel CTO: tips and tricks  ¹ÚÀÇÁØ(°è¸íÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ16:45~16:55 DCB safety: updates of the recent SWEDEPAD trial  ±è¼­¹Î(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ16:55~17:10 (Recorded live case 7) How to use different percutaneous closure devices  Á¶ÁøÇö(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ17:10~17:20 Access related complications: overview and how to avoid them  Á¤ÇõÀç(ºÎ»êÀÇ´ë) 
Åä·Ð 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ17:20~17:30 Discussion  ÀÌ»ó¼ö Á¶ÁøÇö ¹ÚÇü¼· ¿ÀÇàÁø À¯¿µ¼± ÀÌÀçÈÆ(ºÎ»êÀÇ´ë °æÈñÀÇ´ë ¼­¿ïÀÇ´ë ÀÎÁ¦ÀÇ´ë Á¶¼±ÀÇ´ë ´ë±¸°¡Å縯ÀÇ´ë) 
±âŸ 04¿ù 16ÀÏ º¤½ºÄÚ Á¦1Àü½ÃÀå 2Ãþ ȸÀǽǠ17:30~17:40 Closing remarks  Çã½Â(´ëÇÑÇ÷°ü¿Ü°úÇÐȸ ÀÌ»çÀå) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÇ÷°ü¿Ü°úÇÐȸ Á¦73Â÷ Ãá°èÇмú´ëȸ : 2021-04-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2021³â ´ëÇѱٰñ°Ý¿µ»óÀÇÇÐȸ ¿Â¶óÀÎ Á¤±âÇмú´ëȸ : 2021-04-16
´ÙÀ½±Û ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) ¾È°ú ±Ý¿äÁý´ãȸ : 2021-04-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
902 ¼­¿ï Á¦11ȸ ¾Æ½Ã¾Æ¾ÈƼ¿¡ÀÌ¡Çмú´ëȸ : 2018-10-28 0 812 2018-09-12
901 °æ±â Â÷ÀÇ°úÇдëÇб³ºÐ´çÂ÷º´¿ø 2018 CHA International Liver Symposium(¡°Immuno-Oncology for Liver Cancer, Comes of Age!!¡±) : 2018-10-27 0 530 2018-09-12
900 ¼­¿ï ÇѾç´ëÇб³º´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-10-27 0 673 2018-09-12
899 °­¿ø °­¸ª¾Æ»êº´¿ø ¾Ï Áø´Ü°ú Ä¡·áÀÇ ÃÖ½ÅÁö°ß 2018 update : 2018-10-27 0 1,154 2018-09-12
898 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ´ëÇÑôÃß¿Ü°úÇÐȸ 2018 Àü°øÀÇ Ã߰迬¼ö°­Á : 2018-10-27 0 787 2018-09-12
897 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ECHO 360 : 2018-10-27 0 1,198 2018-09-12
896 ´ë±¸ ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2018 Ãß°èÇмú´ëȸ DAY 2 : 2018-10-27 0 366 2018-09-12
895 ¼­¿ï 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ½ÉÈ­±³À°(»çÀüµî·Ï Çʼö) : 2018-10-26 0 412 2018-09-12
894 °æ±â ´Ü±¹´ëÇб³º´¿ø ¾È¼º½Ã ÀÇ»çȸ ¿¬¼ö°­Á : 2018-10-26 0 647 2018-09-12
893 ¼­¿ï 2018 ÀÓ»ó½ÃÇè±Û·Î¹ú¼±µµ¼¾ÅÍ ½ÉÆ÷Áö¾ö (Global Trends in Clinical Trials and Translational Research) : 2018-10-26 0 438 2018-09-12
892 ´ë±¸ ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2018 Ãß°èÇмú´ëȸ DAY 1 : 2018-10-26 0 476 2018-09-12
891 ¼­¿ï 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ½ÉÈ­±³À°(»çÀüµî·Ï Çʼö) : 2018-10-24 0 656 2018-09-12
890 °æ³² °æ»ó³²µµÀÇ»çȸ ³²ºÎ°æ³² ¿¬¼ö±³À° : 2018-10-24 0 1,274 2018-09-12
889 ¼­¿ï ´ëÇѽŻý¾ÆÇÐȸ Á¦1ȸ KNN ½ÉÆ÷Áö¾ö : 2018-10-20 0 913 2018-09-12
888 ¼­¿ï 2018³â À»Áö´ëÇб³ À»Áöº´¿ø È£Èí±â¾Ë·¹¸£±â³»°ú ¿¬¼ö°­Á : 2018-10-20 0 891 2018-09-12
1351 | 1352 | 1353 | 1354 | 1355 | 1356 | 1357 | 1358 | 1359 | 1360
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷